2021 SfN_Trametinib restores memory deficits by activating endogenous neurogenesis in mouse model of Alzheimer’s disease

Repairing damaged neural tissues in patient’s brain is a plausible therapeutic approach for Alzheimer’s disease (AD) and other neurodegenerative diseases. In this study, we report that inhibition of Mitogen-activated protein kinase (Extracellular Receptor Kinase) signaling by trametinib induces generation of new neurons from endogenous neural stem cells in the brain regions affected by the disease and recovers cognitive functions of AD model animals. We propose that trametinib is a promising therapeutic candidate for Alzheimer’s disease.